RxDoctor Payments Data

Kyle Klingler, MD

Ophthalmology · Twin Falls, IDNPI 1861727323

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $280 of the $391 with a category attached, or 71.6%. 9 manufacturers reported payments, led by Rxsight Inc at 35.5% of the total. That places this record below the midpoint for ophthalmology clinicians in ID, where the typical reported total is $971.

$391in general payments, 2019–2025

Across 20 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$139
  • Alcon$76
  • Astellas Pharma US Inc$49
  • Amgen$49
  • Regeneron Healthcare Solutions, Inc.$18
  • Glaukos Corporation$16
  • plus $44 from 3 others

What the payments were for

  • Speaking & faculty fees$6015%
  • Food & beverage$28072%
  • Education$246%
  • Gifts$267%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$391 in reported general payments places this provider in the 25th percentile of 60 ophthalmology providers in Idaho.

See all ophthalmology providers in Idaho

Medicare billing

Part B allowed, 2024
$461,246
Medicare patients
760
Services billed
4,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast42$41,354
RestasisCyclosporine45$35,831
Cyclosporine42$20,819
Prednisolone Acetate314$14,632
RocklatanNetarsudil Mesylat/Latanoprost33$11,663
MoxifloxacinMoxifloxacin Hcl287$9,655
Latanoprost473$3,883
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,793
Timolol Maleate172$1,063
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$1,054
ErythromycinErythromycin Base52$611
Ketorolac Tromethamine21$431
Brimonidine Tartrate30$243
Dorzolamide Hcl15$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$15$35,83145 claims
Aerie Pharmaceuticals, Inc.Rocklatan$14$11,66333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 60 ophthalmology providers in Idaho.

Other ophthalmology in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →